Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York, NY, discusses adjuvant therapy for the treatment of stage III resected high-risk melanoma at WCM/EADO 2021. Dr Weber outlines the use of the PD-1 targeted monoclonal antibodies nivolumab and pembrolizumab, highlighting data from the KEYNOTE-054 trial (NCT02362594) of pembrolizumab versus placebo, and the CheckMate 238 trial (NCT02388906) which is comparing nivolumab and ipilimumab. Dr Weber also gives an overview of the use of dabrafenib and trametinib as well as ipilimumab monotherapy. Finally, Dr Weber summarizes findings from the CheckMate 915 trial (NCT03068455) of nivolumab plus ipilimumab versus nivolumab alone after complete surgical removal of stage III or IV melanoma. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
Jeffrey Weber, MD, PhD, has participated in consultancy work for Merck, Genentech, AstraZeneca, GSK, Novartis, Nektar, Medivation, Celldex, Incyte and EMD Serono; has participated in advisory boards for BMS; holds equity in Celldex, CytoMx and Altor; has participated in scientific advisory boards for Lion Bioscience, Celldex, CytoMx, Incyte and cCam; has received research support from BMS, Merck, GSK, Novartis, AstraZeneca, Mirati and Acetylon; and is named on patent for an ipilimumab biomarker and a PD-1 patent.